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Aim. To compare the basic endocrine proﬁle and outcomes of in vitrofertilization (IVF)in women with polycystic ovary syndrome
(PCOS), ovulatory polycystic ovaries (PCO), or normal ovaries (NO). Methods. The basic clinical features and in vitro fertilization
and embryo transfer outcome in patients receiving IVF or intracytoplasmic sperm injection (ICSI) were retrospectively analyzed.
Results. The body mass index, basal luteinizing hormone, and testosterone levels were signiﬁcantly lower in patients with ovulatory
PCO compared to those in patients with PCOS. The PCOS patients exhibited the shortest duration of ovarian stimulation and
lowest dose of gonadotropin, followed by the ovulatory PCO and NO patients. The ovulatory PCO and PCOS patients showed
similar levels of E2 on the human chorionic gonadotropin treatment day and numbers of oocytes, which were both signiﬁcantly
higher than those of the NO patients. The fertilization rate of the PCOS patients was signiﬁcantly lower than the other two groups.
ComparedtoNOpatients,thecleavageratewaslowerinbothPCOSandovulatoryPCOpatients,however,thenumberofavailable
embryos was signiﬁcantly more in these two groups. The incidence of the moderate to severe ovarian hyperstimulation syndrome
(OHSS)wasmarkedlyhigherinthePCOSandovulatoryPCOpatients.Conclusion.OvulatoryPCOpatientsdonotexpresssimilar
endocrine abnormalities as PCOS patients. Although the fertilization rate and cleavage rate were relatively low in PCOS patients,
ultimately,allthethreegroupsshowedsimilartransferredembryonumbers,clinicalpregnancyrates,andimplantationrates.Since
the incidence of OHSS was much higher in the PCOS and ovulatory PCO patients, we should take more care of these patients and
try to prevent severe OHSS.
1.Introduction
The latest advances in ultrasonic measurement techniques
have helped indentify that 20∼30% women have polycystic
ovaries (PCO) [1]. The incidence of PCO is up to 34% for
those women diagnosed by reproductive specialists [2]. A
subpopulation of these PCO cases is ovulatory PCO [3], in
which women do not display any typical symptom of the
polycystic ovary syndrome (PCOS) although they do have
PCO. Some ovulatory PCO patients reportedly show mild
endocrine abnormalities including high levels of luteinizing
hormone (LH) or androgen as well as insulin resistance,
which are similar to those experienced by PCOS patients
[4–6]. However, a recent study demonstrates that isolated
PCO is an age-dependent, normal ﬁnding among ovulatory
women that has no pathologic or clinical signiﬁcance [7].
To date, numerous studies have extensively investigated the
in vitro fertilization and embryo transfer (IVF-ET) in PCOS
patients [8–13], whereas little information is available for
IVF-ET in ovulatory PCO patients [14–17]. The aim of the
present study was to directly address this deﬁciency in the
literature and compare the ovulation and treatment of IVF-
ET among patients suﬀering from PCOS, ovulatory PCO, or
normal ovaries with other complications (NO).
2.MaterialsandMethods
2.1. Subjects. Patients receiving IVF or intracytoplasmic
sperm injection (ICSI) treatment at the Reproductive Med-
icine Center of the First Aﬃliated Hospital, Sun Yat-sen2 International Journal of Endocrinology
University, between January and September 2010, were
selected for analysis. Patient information was documented in
details, including age, weight, menstruation history, pelvic
ultrasound examination results, and basal hormone levels.
Patients with endometriosis or any other endocrine compli-
cations such as thyroid dysfunction, hyperprolactinemia,
cushingsyndrome,oratypicalcongenitaladrenalhyperplasia
were excluded from the study. Based on the diagnosis,
patients were divided into three groups: PCOS (122 patients,
122 cycles), ovulatory PCO (208 patients, 208 cycles), and
normal ovaries (660 patients, 660 cycles).
There were 122 PCOS patients diagnosed according to
the Rotterdam Standard who had a total of 122 IVF/ICSI
cycles, Oligo-ovulation was deﬁned as a menstrual cycle of
longer than 35 days; hyperandrogenism was diagnosed with
either clinical or biochemical proﬁles; PCO was deﬁned as
the presence of 12 or more follicles in each ovary measuring
2–9mm in diameter, or increased ovarian volume larger
than 10mL. Moreover, 208 ovulatory PCO patients had
208 IVF/ICSI cycles, which were diagnosed with a regular
menstrual cycle (21–35 days), no clinical or biochemical
proﬁles of hyperandrogenism and the presence of 12 or more
follicles with a diameter of 2–9mm in either side of the
ovary, and/or total ovary volume ≥10mL. In addition, 660
patients with normal ovaries had a total of 660 IVF/ICSI
cycles were recruited as controls, they all exhibited normal
ovarian morphology and regular menstrual cycles. Causes
of infertility for these patients include tubal blockage, pelvic
adhesions, and/or male factor.
2.2. IVF-ET. Long-term pituitary downregulation was per-
formed in all patients [18]. Brieﬂy stated, long-acting
gonadotropin-releasing hormone agonist 1.0mg or 1.3mg
was intramuscularly administered in the midluteal phase
(GnRH-a, Diphereline, France). Following pituitary down-
regulation, patients were administered gonadotropin (Gn,
Gonal-F, Switzerland) from the 3th-5th day of the menstrual
cycle. The initial Gn dose was determined by a variety of
factors, including age, number of ovarian follicles, basal FSH
levels, and history of ovarian response. During the ovarian
stimulation, transvaginal ultrasound and serum sex hor-
mone levels were monitored to evaluate the development
of ovarian follicles, and the Gn dose was adjusted based on
the intensity of ovarian response. When more than (and
including) 2 ovarian follicles with the diameter ≥18mm,
or more than (and including) 3 ovarian follicles with the
diameter ≥17mm,weredetected,patientswereinjectedwith
10,000IU human chorionic gonadotropin (hCG, Switzer-
land) to trigger oocyte maturation. Oocytes were collected
about 36 hours later. The fertilization protocol (regular IVF
or ICSI) was determined by the condition of semen on the
same day as the oocyte extraction. Embryo transplantation
was determined by the number of oocytes, the estradiol
(E2) level, and the patient conditions. No more than three
embryos were implanted into the uterine cavity three days
after the oocyte extraction. Patients started receiving hCG or
progesterone treatment since the day of oocyte extraction.
The urine and serum test of hCG was performed 14 days
after embryo transfer. If the hCG test was positive, ultrasonic
examination was conducted two weeks later to determine the
clinical pregnancy.
2.3. Clinical Data Collection. A blood test was performed on
the 2nd-5th day of the menstrual cycle before the treatment
to determine the levels of FSH, LH, E2, and testosterone (T).
The PCOS and ovulatory PCO patients received transvaginal
ultrasound before the IVF treatment to examine the pelvic
conditions. All ovulatory PCO patients and some of the
PCOS patients exhibited the symptoms of polycystic ovary.
During treatment, patient information was documented,
including age, body mass index (BMI), duration of Gn
administration, total Gn dose, E2 levels on the hCG day,
endometrial thickness on the hCG day, numbers of collected
oocytes, fertilization rates, oocyte cleavage rates, numbers
of available embryos and transferred embryos, hCG positive
rates, numbers of gestational sacs, incidence of spontaneous
abortion, incidence of ovarian hyperstimulation syndrome
(OHSS), and incidence of cycle cancellation. The OHSS clas-
siﬁcation was based on the “expert consensus on diagnosis
and treatment of Polycystic Ovarian Syndrome” standard
set by the Endocrinology Group of the Obstetrics and
Gynecology Society, Chinese Medical Association (CMA).
2.4. Data Analysis. A l ld a t aw e r er e p r e s e n t e di nm e a n±
standard deviation (SD). The group diﬀerences were ana-
lyzed by analysis of variance (ANOVA) or rank test for
quantitative data and Chi-square test for qualitative data.
Statistical analyses were ﬁnished using SPSS 13.0 software.
P<0.05 was considered statistically signiﬁcant with Bonfer-
roni corrections.
3. Results
3.1. Basic Clinical Characteristics. Compared to the NO
patients,patientswithPCOSorovulatoryPCOwereyounger
(P<0.01). The PCOS patients exhibited the highest BMI as
w e l la sb a s a lL Ha n dTl e v e l s( P<0.01), whereas the NO
patients exhibited the highest basal FSH levels (P<0.01)
(Table 1).
3.2. Comparisons of Controlled Ovarian Hyperstimulation.
Compared to the NO patients, patients with PCOS or
ovulatory PCO exhibited a signiﬁcantly shorter stimulation
duration and lower Gn dose but showed much higher E2
levels on the hCG treatment day and more achieved oocytes
(P<0.01) (Table 2).
3.3. Comparisons of IVF-ET Outcome. The fertilization rate
of the PCOS patients was signiﬁcantly lower than the other
twogroups.ThePCOSandovulatoryPCOpatientsexhibited
similar lower cleavage rates, but more available embryos. We
did not observe any signiﬁcant diﬀerences in the numbers
of transplanted embryos, pregnancy rates, clinical pregnancy
rates, or implantation rates among the three groups. The
PCOS patients exhibited a higher miscarriage rate (17.5%),
although the diﬀerence was not signiﬁcant. The incidence
of moderate to severe OHSS was 15.8% and 11.1% for the
PCOS and ovulatory PCO patients, respectively, which wasInternational Journal of Endocrinology 3
Table 1: Comparisons of basic clinical features (mean ± SD).
Parameter PCOS Ovulatory PCO NO P-value
Age (year) 30.8 ±3.8( 2 1−42) 30.6 ±3.9( 2 2−41)
c 32.4 ±5.7( 2 1−45)
b 0.000
BMI 22.6 ±3.4a 20.7 ±2.42 0 .8 ±2.7b 0.000
Basal FSH (IU/L) 5.1 ±1.64 .9 ±1.4c 6.4 ±1.7b 0.000
Basal LH (IU/L) 7.3 ±3.7a 5.6 ±2.15 .4 ±1.9b 0.000
Basal E2 (pg/mL) 39.9 ±22.13 6 .8 ±16.83 8 .3 ±21.4 0.772
Testosterone (ng/mL) 1.16 ±0.57a 0.61 ±0.43 0.64 ±0.33b 0.000
N o t e :a :P C O Sv e r s u sP C O ;P<0.01; b: PCOS versus NO; P<0.01; c: PCO versus NO; P<0.01.
Table 2: Comparisons of controlled ovarian hyperstimulation (mean ± SD).
Parameter PCOS Ovulatory PCO NO P-value
Gn duration (day) 10.2 ±1.3a 10.5 ± 1.8c 11.3 ±2.6b 0.000
Total Gn dose (IU) 1843 ±560a 1975 ± 621c 2227 ±765b 0.000
E2 (hCG day) (pg/mL) 3071 ±2637 3162 ±2716c 2465 ±1879b 0.000
Endometrial thickness
(HCG day) (mm) 11.3 ±3.51 0 .8 ±2.31 0 .9 ±2.6 0.262
Number of oocytes 16.5 ±8.61 7 .1 ±7.4b 11.7 ±6.9c 0.000
N o t e :a :P C O Sv e r s u sP C O ;P<0.01; b: PCOS versus NO; P<0.01; c: PCO versus NO; P<0.01.
signiﬁcantly higher than that of the NO patients (5.4%, P<
0.01) (Table 3).
Besides moderate to severe OHSS, cycle cancellation
was also a notable adverse outcome of the IVF treatment.
Cycle cancellation could be classiﬁed into three types: (1)
the cycle was canceled during the process of ovarian stim-
ulation because of poor ovarian response; (2) the embryo
transfer was canceled due to excessive numbers of oocyte
achieved, high E2 levels on the hCG treatment day, and/or
showing symptoms of overstimulation, including abdominal
distensionandapparentpelvicﬂuid;(3)othercomplications,
including oocyte collection failure, abnormalities in the
oocyte fertilization and/or cleavage, poor embryo quality,
and/or endometrial factors. In the PCOS, ovulatory PCO,
and NO patients, the rates of cycle cancellation due to poor
ovarian response were 1.6% (2/122), 0% (0/208), and 2.7%
(16/660), respectively; the rates of embryo transfer can-
cellation were 18.0% (22/122), 22.1% (46/208), and 4.9%
(32/660), respectively; the rates of other causes were 1.6%
(2/122),1.0%(2/208),and2.4%(16/660),respectively.Thus,
the overall rates of cycle cancellation for these three groups
were 21.2% (26/122), 23.1% (48/208), and 10.0% (64/660),
respectively. Our results suggested that compared to the NO
patients, the PCOS and ovulatory PCO patients exhibited
signiﬁcantly higher rates of embryo transfer cancellation and
overall cycle cancellation (P<0.05).
4. Discussion
Contrary to some reports [4–6], in the current study, we
found that BMI and levels of LH and androgen were similar
between the ovulatory PCO and NO patients, which were
signiﬁcantly higher than those in the PCOS patients. Insulin-
sensitizing agent metformin which has been examined as a
cotreatment during IVF in women with PCOS, brought an
increase in pregnancy rate [19] and a signiﬁcant reduction
in rates of OHSS [20], however, for women with PCO but
no other manifestations of PCOS, metformin cotreatment
before and during IVF did not bring any positive eﬀect in
clinical pregnancy, live birth, or severe OHSS [21]. The most
likely explanation is that women with PCO may be less
insulin resistance compared with women with PCOS. While
some women with PCO to share some endocrinological
abnormalities with those with PCOS, the diﬀerence between
these studies may be attributed to variations in categorizing
patients. According to the widely used Rotterdam diagnostic
criteria for PCOS, ultrasonic diagnosis of PCO is an impor-
tant,butnotessentialcharacteristicofPCOS.Thus,PCOand
PCOS are not necessarily related to each other. In this study,
the ovulatory PCO patients did not have the endocrine and
metabolic abnormalities manifested by the PCOS patients,
indicating that polycystic ovary might only represent some
normal variation in the ovarian morphology.
All patients in the present study were treated with
standard protocol of long-term GnRH-a administration in
midluteal phase, which was commonly used for infertility
women including PCOS patients. In addition to its well-
known advantages such as easy to operate and satisfactory
pregnancy rates, for PCOS patients, GnRH-a can eﬀectively
reduce the LH/androgen level and inhibit the inﬂammatory
factors, thus may improve the quality of the oocytes and
e m b r y o sa sw e l la se n d o m e t r i a lr e c e p t i v i t y .C o m p a r e dw i t h
the PCOS patients treated with oral contraceptive pill [OCP]
alone, patients treated with OCP plus long-term GnRH ago-
nist exhibit lower hormone levels and better amelioration of
clinical symptoms [8–10]. In addition, the fertilization rates
and pregnancy rates of GnRH-a-treated PCO patients were
similar to those of the non-PCO patients [14]. Therefore,
based on the current ﬁndings, clinical experience, as well as
our ﬁndings in the present study, we propose that GnRH-a4 International Journal of Endocrinology
Table 3: Comparisons of IVF-ET outcome.
Parameter PCOS Ovulatory PCO NO P-value
%o ff e r t i l i z a t i o n( I V F
cycle) 69.2 (950/1373)
a 76.9 (1797/2338) 78.6 (6223/7922)
b 0.000
%o fo o c y t ec l e a v a g e 8 7 .4 (830/950) 86.1 (1547/1797)
c 91.8 (5713/6223)
b 0.000
Available embryos 9.3 ±5.91 0 .6 ± 5.7c 6.3 ±4.2b 0.000
Transferred embryos 2.2 ±0.52 .3 ±0.52 .3 ±0.6 0.723
%o fp r e g n a n c y 5 1 .0( 5 0 /98) 53.2( 6 7 /126) 47.2 (274/580) 0.423
% of clinical pregnancy 40.8( 4 0 /98) 43.7( 5 5 /126) 39.3 (228/580) 0.667
% of implantation 25.5( 5 6 /220) 26.0( 7 5 /288) 24.7 (328/1328) 0.878
%o fm i s c a r r i a g e 1 7 .5( 7 /40) 10.9( 6 /55) 8.8( 2 0 /228) 0.244
%o fO H S S 1 5 .8( 1 9 /120) 11.1( 2 3 /208)
c 5.4( 3 4 /626)
b 0.000
N o t e :a :P C O Sv e r s u sP C O ;P<0.01; b: PCOS versus NO; P<0.01; c: PCO versus NO; P<0.01.
long-term protocol is suitable strategy for the PCOS patients
treated with IVF.
Our study showed that both the ovulatory PCO and
PCOS patients displayed high-ovarian responsiveness, which
was consistent with previous research [15]. Compared to
the NO patients, the ovulatory PCO and PCOS patients
exhibited reduced duration of ovarian stimulation and total
Gn dose, as well as increased E2 levels and number of
collected oocytes. Previous studies have suggested that com-
pared to other infertility patients, PCOS patients exhibited
a higher degree of ovary vascularization during the pro-
cess of ovarian stimulation, which paralleled with vascular
endothelial growth factor [VEGF] levels in the serum and
follicular ﬂuid. The ovary vascularization and VEGF levels
were positively correlated with the E2 levels and numbers of
oocytesachieved[11,22].Inaddition,VEGFcanenhancethe
proliferation and function of granulosa cells [23]. Coﬄer et
al. [12] suggest that in PCOS patients, follicular granulosa
cells can show two types of response to FSH: (1) PCOS
patientsshowremarkablyhigherE2levelsinresponsetoFSH
above the threshold dose; (2) PCOS patients treated with a
single FSH stimulation exhibit much faster rise and decay of
the E2 levels, which were much diﬀerent from the response
of the control patients. However, serum FSH levels of both
groups were similar, a phenomenon which is probably
explained by the fact that most follicular granulosa cells have
either apoptosed or cannot eﬀectively respond to FSH.
Basedonpreviousandcurrentﬁndings,weconcludethat
both PCOS and ovulatory PCO patients are sensitive to Gn
stimulation, thus it is diﬃcult to determine an appropriate
Gn dose for each individual patient. In our study, although
we gradually reduced the Gn dose to avoid such overstimula-
tion, the follicle degeneration and atresia were still observed
in some patients, which were also reported by Coﬄer et al.
[12]. Further work is needed to address this issue.
Compared to the NO patients, the PCOS but not the
ovulatory PCO patients showed lower fertilization rates,
whereas both groups exhibited a signiﬁcantly lower oocyte
cleavage rates and more available embryos. Thus, we further
investigatedwhetherthelowerfertilizationratesofthePCOS
patients were due to abnormal oocyte morphology or chan-
ges in cytosolic factors which could aﬀect the quality of the
oocytes. Previous studies report that the morphology of the
cytoplasm and extra cellular matrix of the oocytes and em-
bryos were similar among the PCOS, PCO, and NO patients,
indicating that the aﬀected fertilization and early embryonic
development of the PCOS and/or PCO patients are not be-
cause of intrinsic abnormalities of the oocytes [24].
Endocrine disorders and internal oocyte abnormalities
can also result in low rates of oocyte fertilization and cleav-
age. For instance, high LH levels and insulin resistance can
causethemalfunctionoffolliculargranulosacellsandtheab-
normal expression of GDF-9, both of which markedly reduce
the quality of the embryos [3, 14, 25].
Our results also demonstrated that the ovulatory PCO
and PCOS patients exhibited similar rates of pregnancy,
clinical pregnancy, and implantation. Although the higher
averageageoftheNOpatientsmightbeaconfoundingfactor
for the analysis, we still considered that the pregnancy rates
of the ovulatory PCO and PCOS patients were satisfactory.
Our observations were consistent with previous studies by
Esmailzadeh et al. [14], Kim et al. [15], Swanton et al. [16],
and Esinler et al. [17]. In Esmailzadeh et al., the fertilization
and pregnancy rates of the ovulatory PCO patients treated
with GnRH-a long-term protocol were similar to those of
the non-PCO patients [14]. Similar outcomes (duration
of stimulation, dose of Gn used, E2 level on hCG day,
number of retrieved oocytes, rates of implantation, clinical
pregnancy and miscarriage, any incidence of severe OHSS)
were observed in patients with PCOS and sonographic PCO-
only for IVF-ET treatment [15]. Live birth rates are similar
among women with PCO (38%), PCOS (37%), and normal
ovaries (40%). Severe OHSS rates were signiﬁcantly higher
in women with PCO (12.6%) and PCOS (15.4%) compared
to those with normal ovaries (2.7%) [16]. In the study of
Esinleretal.,thesatisfactorypregnancyratesoftheovulatory
PCO and PCOS patients were due to suﬃcient numbers of
collected oocytes, fertilized oocytes, and transferred high-
quality embryos [17].
PCOS patients exhibited the highest abortion rate,
although no signiﬁcant diﬀerence was detected, which could
be explained by smallsample size and agevariation. Whether
this high risk of abortion is related to the quality of the
oocytes remains unclear. The risk may as well be caused byInternational Journal of Endocrinology 5
other factors than the oocytes. For instance, central obesity
patients exhibit high LH levels and insulin resistance which
can cause abortion, whereas administration of GnRH-a to
these patients can eﬀectively reduce the risk of abortion [24].
Wang et al. [13] postulated that the relatively high abortion
rates in the PCOS patients were due to combined eﬀects
of obesity, treatment for infertility, and causes of infertility.
After correction for these factors, the abortion rates in the
PCOS patients were comparable to those in the controls,
indicatingthattheintrinsicfactorsofPCOScontributedlittle
to the abortion issue. In addition, the high E2 levels induced
by ovary stimulation might increase the risk for abortion
by lowering the endometrial capacity. However, both the
viewpoints need further research for veriﬁcation.
In summary, a subpopulation of polycystic ovaries cases
are called ovulatory PCO patients, who do not display high
levels of androgen and have regular menstrual cycles al-
though they do have PCO. Unlike the PCOS patients, they
have almost normal endocrine and metabolic characteristics
and their PCO may be a normal variation of ovary morphol-
ogy. When treated with IVF-ET, ovulatory PCO and PCOS
patients similarly manifest high ovarian responsiveness, rel-
atively good IVF pregnancy rates, and incidence of adverse
outcomes, including high OHSS risk, cycle cancellation rates
and abortion rates (although the diﬀerences were not statis-
tically signiﬁcant).
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